Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Pulmonary Hypertension
Interventions: NX1011; Drug
Lead sponsor: NITROX, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Phoenix, Arizona • La Jolla, California • Newark, Delaware + 3 more

Conditions: OBESITY, HYPERTENSION, PURE AUTONOMIC FAILURE, SHY-DRAGER SYNDROME
Interventions: Trimethaphan, Pseudoephedrine; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension, Uncontrolled Hypertension, Hypertension, White Coat, Hypertension, Resistant to Conventional Therapy
Interventions: Blood pressure measurement device; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Medication Adherence, High Blood Pressure, Diabetes
Interventions: Comparison to peers, Adherence feedback, Electronic pill bottle; Behavioral · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Pregnancy Induced, Hypertension Complicating Pregnancy, Preeclampsia, Cardiovascular Diseases, Patient Engagement
Interventions: Decision aid; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
Interventions: brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution; Drug · Other
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2036
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Glaucoma, Open-Angle, Failing Bleb Following Trabeculectomy
Interventions: Ranibizumab (Lucentis); Drug
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 40 Years and older
Enrollment: 6 participants
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Interventions: NS-863 Low Dose, NS-863 High Dose, Placebo; Drug · Other
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Pulmonary Hypertension Due to Left Heart Disease
Interventions: Treprostinil Diolamine; Drug
Lead sponsor: Mardi Gomberg -Maitland MD, MSc; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: Self-affirmation exercise, Control; Behavioral
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 21 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction, Pulmonary Vascular Disorder
Interventions: Valsartan 40 mg, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions: Cannabis, Medical, RYAH-Medtech Inhaler; Drug · Device
Lead sponsor: OMNI Medical Services, LLC; Network
Eligibility: 7 Years and older
Enrollment: 200,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more

Conditions: Hypertension
Interventions: Enhanced External Counterpulsation; Device
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: OrCam; Device
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Arterial Hypertension
Interventions: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: Fresno, California • Torrance, California • Orlando, Florida + 8 more

Conditions: Glaucoma
Interventions: Ahmed FP7 Valve, Baerveldt-350 Tube; Device
Lead sponsor: Credit Valley EyeCare; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 3
States / cities: Indianapolis, Indiana • Nashville, Tennessee • Milwaukee, Wisconsin

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions: Paradise Renal Denervation System, Renal Angiogram; Device · Procedure
Lead sponsor: ReCor Medical, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Bridgeport, Connecticut + 24 more

Conditions: CTEPH
Interventions: Macitentan Tablets, Riociguat, balloon pulmonary angioplasty; Drug · Device
Lead sponsor: Dr Sudarshan Rajagopal; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Portopulmonary Hypertension
Interventions: Ambrisentan; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 6
States / cities: La Jolla, California • Jacksonville, Florida • Boston, Massachusetts + 3 more

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution; Drug
Lead sponsor: Aerpio Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Austin, Texas • Dallas, Texas

Conditions: Renal Disease, High Blood Pressure
Interventions: Not listed
Lead sponsor: Renal Research Institute; Other
Eligibility: 18 Years to 88 Years
Enrollment: 12,695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Essential Hypertension
Interventions: Motivational Interviewing; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, Study# 2 chlorthalidone (CTD), fixed dose, Study# 2 spironolactone (SP), fixed dose, Study# 2 irbsesartan (IR), fixed dose; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Acute Kidney Injury, Cirrhosis, Portal Hypertension, Hepatorenal Syndrome, Acute Tubule Necrosis, Prerenal Failure
Interventions: MAP-Target Algorithm; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension

The Autonomic Nervous System and Obesity

Use of Automated Office Blood Pressure Monitoring

Social Forces to Improve Statin Adherence (Study B)

Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

Treatment of Failing Blebs With Ranibizumab

A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Telemonitoring to Treat Group 2 Pulmonary Hypertension

An Intervention to Improve Communication Between Physicians and Minority Patients With Hypertension

Repurposing Valsartan May Protect Against Pulmonary Hypertension

Outcomes Mandate National Integration With Cannabis as Medicine

Role of Enhanced External Counterpulsation (EECP) Therapy in Patients With Resistant Hypertension

Does Using a Low Vision Aid Device Improve Quality of Life in Glaucoma Patients?

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Blood Pressure Change and Outcome

Motivational Interviewing

Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients